Headlines

Tilray Stock Bearish Momentum With A 30% Slide In The Last 10 Sessions

(VIANEWS) – Shares of Tilray (NASDAQ: TLRY) fell by a staggering 30.71% in 10 sessions from $2.41 at 2023-05-17, to $1.67 at 23:22 EST on Wednesday, after five successive sessions in a row of losses. NASDAQ is falling 0.63% to $12,935.29, following the last session’s downward trend.

Tilray’s last close was $1.67, 67.7% below its 52-week high of $5.17.

About Tilray

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.

Earnings Per Share

As for profitability, Tilray has a trailing twelve months EPS of $-2.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.15%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 94.4% and 61.5%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth declined by 4.1%, now sitting on 596.26M for the twelve trailing months.

More news about Tilray (TLRY).

Leave a Reply

Your email address will not be published. Required fields are marked *